ICML 2019 | Combo of RG6146/venetoclax/rituximab for R/R DLBCL: initial data

Michael Dickinson

Michael Dickinson, MBBS, DMedSc, FRACP, FRACPA, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses the combination of the BET inhibitor RG6146, venetoclax and rituximab in relapsed/refractory diffuse large B-cell lymphoma (DLBCL). He reports the initial Phase Ib safety, biomarker and response data (NCT03255096). This interview took place at the 15th International Conference on Malignant Lymphoma (ICML), in Lugano, Switzerland.

Share this video